F-star Therapeutics Accounts Payable

F-star Therapeutics's accounts payable stands at $2.5M as of September 2022. That compares with $1.6M in the prior-year period — up 59.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

F-star Therapeutics reported $2.5M in accounts payable versus $1.6M a year earlier — a 59.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.6M in the prior-year period — up 59.4% year over year. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how F-star Therapeutics's accounts payable evolved across reporting periods, while the comparison chart places FSTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. F-star Therapeutics's reading of $2.5M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.